Prezzo di chiusura
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
15,5 USD | -7,19% | -1,90% | +42,76% |
Attività
- endocrinologia (57,7%): prodotti per il trattamento dell'osteoporosi, del diabete e dei problemi di crescita;
- oncologia (19,5%);
- malattie immunologiche (11,1%);
- neurologia (8,4%): principalmente farmaci utilizzati nel trattamento della depressione e della schizofrenia;
- altro (3,3%).
Le vendite nette sono distribuite geograficamente come segue: Stati Uniti (63,9%), Europa (18,1%), Giappone (4,9%), Cina (4,5%) e altro (8,6%).
Numero di dipendenti: 43 000
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80% |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62% |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30% |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28% |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/10/23 |
Alonzo Weems
CMP | Compliance Officer | - | 01/01/97 |
Chief Tech/Sci/R&D Officer | 50 | 01/01/18 | |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17/05/21 |
Johna Norton
PRN | Corporate Officer/Principal | 57 | 01/04/17 |
Corporate Officer/Principal | - | 01/01/05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
- | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 63 | 25/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/04/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/01/05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01/02/16 |
William Kaelin
BRD | Director/Board Member | 66 | 04/06/12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01/10/16 |
Director/Board Member | 52 | 12/12/11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01/09/13 |
Karen Walker
BRD | Director/Board Member | 62 | 01/12/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 950 770 386 | 948 828 714 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 124 808 142 $ |
8 084 411 | 6.83% | 44 026 813 $ | |
PROQR THERAPEUTICS N.V. 16.37% | 13 371 562 | 16.37% | 26 074 546 $ |
4 000 000 | 7.23% | 23 320 000 $ | |
AC IMMUNE SA 3.64% | 3 615 328 | 3.64% | 16 811 275 $ |
21 776 804 | 7.60% | 10 995 108 $ | |
125 405 | 1.81% | 1 617 725 $ |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Kinsale Financial Services
| |
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Lilly Ventures Fund I LLC
Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Eli Lilly Group Pension Trustees Ltd.
Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The company is based in Basingstroke, UK. |
Financial Conglomerates
|
Eli Lilly (Suisse) SA
| |
Eli Lilly Vostok SA
| |
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+41,96% | 627 Mrd | |
-7,15% | 350 Mrd | |
+18,77% | 328 Mrd | |
+8,79% | 294 Mrd | |
+18,02% | 245 Mrd | |
+1,27% | 222 Mrd | |
+11,95% | 215 Mrd | |
+3,68% | 160 Mrd | |
-4,38% | 157 Mrd |
- Borsa valori
- Azioni
- Azione LLY
- Azione LLYD
- Società Eli Lilly and Company